TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
XENE

Xenon Pharmaceuticals Inc

Healthcare · Biotechnology

57.40$ +1.0% vs. previous close Closing price · As of: Sep 17, 2026

Statements

Income Statement

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Income Statement XENE
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
20.8% 17.7% 61.8% 8,222.8% 568.8% 157.1% 409.3% 1,121.1% 33.9%
79.2% 100.0% 38.2% -8,122.8% 100.0% 100.0% 100.0% 100.0% 66.1%
41.5% 97.3% 1,099.7% 8,222.8% 568.8% 157.1% 409.3% 1,121.1% 4,012.5%
19.4% 62.8% 376.7% 2,351.4% 158.2% 40.2% 119.1% 347.8% 1,061.8%
60.9% 160.1% 1,476.4% 10,574.3% 727.0% 197.3% 528.4% 1,468.9% 5,040.4%
39.1% -60.1% -1,376.4% -10,474.3% -627.0% -97.3% -428.4% -1,368.9% -4,974.3%
0.0% 0.0% 0.0% 0.0% 21.0% 1.5% 5.5% 58.4%
45.9% -101.1% -1,275.5% -9,872.7% -609.4% -90.4% -427.9% -1,327.7% -4,598.6%
0.0% -6.7% -100.9% -601.6% -0.3% -0.8% 0.0% 1.3% 13.5%
45.9% -101.1% -1,275.5% -9,872.7% -609.1% -89.7% -427.8% -1,328.9% -4,612.1%
41.7% -53.4% -1,328.5% -9,664.0% -582.1% -95.3% -423.5% -1,351.7% -4,564.7%

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?